Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
